{"id":499664,"date":"2026-01-07T20:03:12","date_gmt":"2026-01-07T20:03:12","guid":{"rendered":"https:\/\/www.europesays.com\/us\/499664\/"},"modified":"2026-01-07T20:03:12","modified_gmt":"2026-01-07T20:03:12","slug":"milestone-announces-acceptance-of-maa-by-ema-for-etripamil-nasal-spray","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/499664\/","title":{"rendered":"Milestone announces acceptance of MAA by EMA for etripamil nasal spray"},"content":{"rendered":"\n<p class=\"yf-vbsvxt\">Milestone Pharmaceuticals (<a href=\"https:\/\/www.tipranks.com\/stocks\/mist?utm_source=finance.yahoo.com&amp;utm_medium=referral\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:MIST;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">MIST<\/a>) announced the acceptance of a Marketing Authorization Application, MAA, by the European Medicines Agency, EMA, seeking the approval of etripamil nasal spray, developed to be the first rapid, reliable option in the treatment of paroxysmal supraventricular tachycardia, PSVT, outside of the healthcare setting. Etripamil, which has the conditionally approved brand name TACHYMIST in Europe, is an investigational, novel calcium channel blocker delivered via a nasal spray by the patient for the potential treatment of PSVT and other cardiac arrhythmias. A decision on approval is expected by the first quarter of 2027.<\/p>\n<p class=\"yf-vbsvxt\">Published first on <a href=\"https:\/\/thefly.com\/?utm_source=finance.yahoo.com&amp;utm_medium=referral\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:TheFly;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">TheFly<\/a> \u2013 the ultimate source for real-time, market-moving breaking financial news. <a href=\"https:\/\/thefly.com\/?utm_source=finance.yahoo.com&amp;utm_medium=referral\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Try Now&gt;&gt;;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">Try Now&gt;&gt;<\/a><\/p>\n<p class=\"yf-vbsvxt\"><a href=\"https:\/\/www.tipranks.com\/screener\/top-insider-trading-stocks\/?type=stockAnalysisLanding&amp;utm_source=finance.yahoo.com&amp;utm_medium=referral\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:See Insiders\u2019 Hot Stocks on TipRanks &gt;&gt;;elm:context_link;itc:0;sec:content-canvas\" class=\"link \"><strong>See Insiders\u2019 Hot Stocks on TipRanks &gt;&gt; <\/strong><\/a><\/p>\n<p class=\"yf-vbsvxt\"><strong>Read More on MIST:<\/strong><\/p>\n<p class=\"yf-vbsvxt\"><a href=\"https:\/\/www.tipranks.com\/glossary\/d\/disclaimer-disclosure\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Disclaimer &amp; Disclosure;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">Disclaimer &amp; Disclosure<\/a><a href=\"https:\/\/www.tipranks.com\/glossary\/c\/contact-editor\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Report an Issue;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">Report an Issue<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Milestone Pharmaceuticals (MIST) announced the acceptance of a Marketing Authorization Application, MAA, by the European Medicines Agency, EMA,&hellip;\n","protected":false},"author":3,"featured_media":499665,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[224295,224293,189904,210,1060,224292,224294,193363,67,132,68],"class_list":{"0":"post-499664","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-acceptance","9":"tag-cardiac-arrhythmias","10":"tag-european-medicines-agency","11":"tag-health","12":"tag-medication","13":"tag-milestone-pharmaceuticals","14":"tag-mist","15":"tag-nasal-spray","16":"tag-united-states","17":"tag-unitedstates","18":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115855609923488917","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/499664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=499664"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/499664\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/499665"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=499664"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=499664"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=499664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}